I have 30 years of experience, and specialize in the pharmaceutical field with specific knowledge in the areas of medicinal chemistry, oncology and metabolic diseases. I have published on such topics as antitumor activity and the pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor.